patient_id stringlengths 12 12 | record_id stringlengths 11 11 | cancer_type stringclasses 1
value | histology stringclasses 3
values | stage_at_diagnosis stringclasses 3
values | driver_mutation stringclasses 7
values | pd_l1_tps_percent int64 5 41 | tmb_mutations_per_mb float64 1.5 25 | age_at_diagnosis int64 38 90 | sex stringclasses 2
values | ecog_performance_status int64 0 4 | smoking_pack_years int64 0 111 | primary_tumor_size_cm float64 2 10 | metastatic_sites_count int64 0 11 | first_line_regimen stringclasses 6
values | overall_survival_months float64 4 83 | censored bool 2
classes | msi_status stringclasses 2
values | record_generation_timestamp stringdate 2026-03-15 05:35:56 2026-03-15 05:36:02 | synthetic_source stringclasses 1
value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ANODE_723984 | REC_0006101 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 23 | 4.2 | 41 | male | 0 | 49 | 6.3 | 5 | carboplatin + paclitaxel + pembrolizumab | 9.4 | false | MSS | 2026-03-15T05:35:58.353201+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_390549 | REC_0006102 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 23 | 1.5 | 74 | female | 1 | 22 | 4.9 | 2 | alectinib 600 mg BID | 16.7 | true | MSS | 2026-03-15T05:35:58.353429+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_765507 | REC_0006103 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 23 | 7.5 | 84 | female | 2 | 18 | 4.4 | 1 | carboplatin + paclitaxel + pembrolizumab | 13.5 | true | MSS | 2026-03-15T05:35:58.353662+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_596350 | REC_0006104 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 25 | 10.2 | 60 | male | 1 | 5 | 5.8 | 6 | alectinib 600 mg BID | 13.6 | false | MSS | 2026-03-15T05:35:58.353897+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_934372 | REC_0006105 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 32 | 3.7 | 68 | female | 1 | 26 | 2.8 | 4 | sotorasib 960 mg daily | 11.5 | true | MSS | 2026-03-15T05:35:58.354124+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_692843 | REC_0006106 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 29 | 15.7 | 77 | male | 0 | 26 | 4.5 | 8 | sotorasib 960 mg daily | 10.4 | false | MSI-H | 2026-03-15T05:35:58.354359+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_320575 | REC_0006107 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 27 | 11.5 | 52 | male | 0 | 18 | 5.8 | 1 | osimertinib 80 mg daily | 25.1 | false | MSI-H | 2026-03-15T05:35:58.354594+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_336373 | REC_0006108 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 30 | 7.1 | 61 | female | 1 | 88 | 3.8 | 2 | carboplatin + paclitaxel + pembrolizumab | 25.2 | false | MSS | 2026-03-15T05:35:58.354826+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_591663 | REC_0006109 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 32 | 8.2 | 58 | female | 0 | 73 | 4.8 | 5 | carboplatin + paclitaxel + pembrolizumab | 6.5 | false | MSS | 2026-03-15T05:35:58.355061+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_791119 | REC_0006110 | Non-small cell lung cancer | Adenocarcinoma | IVA | None (PD-L1 high) | 31 | 12.6 | 57 | male | 0 | 17 | 4.6 | 2 | pembrolizumab 200 mg q3w | 20.7 | false | MSI-H | 2026-03-15T05:35:58.355297+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_421840 | REC_0006111 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 19 | 8.6 | 77 | male | 1 | 5 | 5.1 | 8 | pembrolizumab 200 mg q3w | 10.6 | true | MSS | 2026-03-15T05:35:58.355578+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_608834 | REC_0006112 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 24 | 9.2 | 68 | female | 1 | 18 | 6.1 | 7 | osimertinib 80 mg daily | 10.6 | true | MSS | 2026-03-15T05:35:58.355811+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_814644 | REC_0006113 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 25 | 10.5 | 61 | male | 1 | 15 | 5.2 | 2 | sotorasib 960 mg daily | 20.8 | false | MSI-H | 2026-03-15T05:35:58.356046+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_930718 | REC_0006114 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 16 | 7.7 | 78 | female | 3 | 6 | 3.2 | 2 | osimertinib 80 mg daily | 4 | false | MSS | 2026-03-15T05:35:58.356485+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_303957 | REC_0006115 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 30 | 8.1 | 66 | female | 0 | 20 | 3.6 | 7 | osimertinib 80 mg daily | 19 | false | MSS | 2026-03-15T05:35:58.356716+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_285101 | REC_0006116 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 23 | 5.9 | 65 | female | 1 | 13 | 6.2 | 2 | pembrolizumab 200 mg q3w | 9.9 | false | MSS | 2026-03-15T05:35:58.356948+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_756584 | REC_0006117 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 28 | 20.1 | 60 | female | 0 | 11 | 4 | 4 | alectinib 600 mg BID | 10.6 | false | MSI-H | 2026-03-15T05:35:58.357186+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_599701 | REC_0006118 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 26 | 12.2 | 79 | female | 2 | 24 | 5.2 | 6 | osimertinib 80 mg daily | 13.3 | false | MSI-H | 2026-03-15T05:35:58.357418+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_344505 | REC_0006119 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 33 | 9.5 | 59 | female | 0 | 17 | 6.9 | 5 | alectinib 600 mg BID | 13.4 | true | MSS | 2026-03-15T05:35:58.357650+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_119215 | REC_0006120 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 19 | 5.2 | 61 | male | 0 | 15 | 3.8 | 7 | alectinib 600 mg BID | 8.5 | true | MSS | 2026-03-15T05:35:58.357882+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_651127 | REC_0006121 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 32 | 10.4 | 63 | male | 0 | 18 | 3.5 | 0 | osimertinib 80 mg daily | 8.8 | false | MSS | 2026-03-15T05:35:58.358116+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_777846 | REC_0006122 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 28 | 14.5 | 57 | female | 1 | 6 | 5.3 | 5 | alectinib 600 mg BID | 12.1 | true | MSS | 2026-03-15T05:35:58.358352+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_576617 | REC_0006123 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 32 | 14 | 55 | male | 0 | 23 | 4.5 | 5 | alectinib 600 mg BID | 9.4 | true | MSS | 2026-03-15T05:35:58.358589+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_850248 | REC_0006124 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 20 | 4.4 | 71 | female | 2 | 48 | 5.9 | 1 | carboplatin + paclitaxel + pembrolizumab | 40.9 | false | MSS | 2026-03-15T05:35:58.358872+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_463687 | REC_0006125 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 24 | 8.1 | 60 | male | 1 | 17 | 7 | 4 | osimertinib 80 mg daily | 7.9 | true | MSS | 2026-03-15T05:35:58.359111+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_570740 | REC_0006126 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 23 | 12.4 | 78 | female | 1 | 23 | 5.2 | 5 | osimertinib 80 mg daily | 9.4 | false | MSI-H | 2026-03-15T05:35:58.359347+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_593237 | REC_0006127 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 23 | 8.4 | 62 | male | 1 | 33 | 7.5 | 7 | carboplatin + paclitaxel + pembrolizumab | 5.4 | true | MSS | 2026-03-15T05:35:58.359584+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_658915 | REC_0006128 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 24 | 4.8 | 75 | female | 1 | 71 | 6.8 | 5 | carboplatin + paclitaxel + pembrolizumab | 9.1 | false | MSS | 2026-03-15T05:35:58.359814+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_814368 | REC_0006129 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 23 | 10.9 | 63 | male | 0 | 10 | 4.6 | 5 | pembrolizumab 200 mg q3w | 11.6 | false | MSS | 2026-03-15T05:35:58.360050+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_928914 | REC_0006130 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 22 | 9.9 | 83 | female | 1 | 16 | 5.6 | 6 | sotorasib 960 mg daily | 13.4 | true | MSS | 2026-03-15T05:35:58.360327+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_395083 | REC_0006131 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 19 | 8.2 | 74 | male | 2 | 9 | 3.6 | 1 | sotorasib 960 mg daily | 23.1 | true | MSS | 2026-03-15T05:35:58.360565+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_729366 | REC_0006132 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 29 | 15.9 | 60 | male | 1 | 1 | 4.3 | 6 | entrectinib 600 mg daily | 14.2 | false | MSS | 2026-03-15T05:35:58.360801+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_144182 | REC_0006133 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None (PD-L1 high) | 30 | 5.7 | 59 | male | 0 | 45 | 5.9 | 1 | pembrolizumab 200 mg q3w | 16.1 | false | MSS | 2026-03-15T05:35:58.361035+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_995774 | REC_0006134 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 30 | 5.5 | 75 | male | 3 | 16 | 6.7 | 1 | osimertinib 80 mg daily | 17.3 | true | MSS | 2026-03-15T05:35:58.361269+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_341043 | REC_0006135 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 29 | 9 | 63 | female | 1 | 17 | 4.4 | 2 | alectinib 600 mg BID | 13.4 | true | MSS | 2026-03-15T05:35:58.361507+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_553414 | REC_0006136 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 26 | 12.8 | 75 | female | 1 | 19 | 6.5 | 5 | entrectinib 600 mg daily | 8.6 | false | MSS | 2026-03-15T05:35:58.361737+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_211462 | REC_0006137 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 21 | 10 | 63 | female | 1 | 15 | 3.1 | 6 | alectinib 600 mg BID | 12 | false | MSS | 2026-03-15T05:35:58.362055+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_892227 | REC_0006138 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 28 | 1.5 | 72 | female | 2 | 53 | 6.2 | 2 | carboplatin + paclitaxel + pembrolizumab | 21.3 | true | MSS | 2026-03-15T05:35:58.362292+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_623397 | REC_0006139 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 23 | 7.8 | 78 | female | 1 | 15 | 6.7 | 7 | entrectinib 600 mg daily | 5.6 | false | MSS | 2026-03-15T05:35:58.362527+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_125511 | REC_0006140 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 21 | 13.6 | 70 | female | 1 | 10 | 6.9 | 5 | sotorasib 960 mg daily | 13.1 | true | MSS | 2026-03-15T05:35:58.362765+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_769404 | REC_0006141 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 25 | 8.2 | 59 | female | 1 | 59 | 6.8 | 1 | carboplatin + paclitaxel + pembrolizumab | 21.9 | false | MSS | 2026-03-15T05:35:58.363001+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_748455 | REC_0006142 | Non-small cell lung cancer | Adenocarcinoma | III | ROS1 fusion | 22 | 10.4 | 69 | female | 1 | 23 | 7.8 | 0 | entrectinib 600 mg daily | 44 | false | MSS | 2026-03-15T05:35:58.363239+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_413176 | REC_0006143 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 32 | 8.3 | 70 | female | 2 | 16 | 5.3 | 7 | pembrolizumab 200 mg q3w | 14.5 | true | MSS | 2026-03-15T05:35:58.363470+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_119837 | REC_0006144 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 37 | 10.1 | 69 | female | 1 | 21 | 5.6 | 4 | osimertinib 80 mg daily | 15.2 | false | MSI-H | 2026-03-15T05:35:58.363708+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_128707 | REC_0006145 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 20 | 10.1 | 64 | male | 1 | 27 | 5.6 | 1 | osimertinib 80 mg daily | 16.3 | false | MSI-H | 2026-03-15T05:35:58.363945+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_292163 | REC_0006146 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 31 | 8.8 | 77 | female | 2 | 22 | 5.6 | 1 | carboplatin + paclitaxel + pembrolizumab | 14.5 | true | MSS | 2026-03-15T05:35:58.364247+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_381970 | REC_0006147 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 29 | 1.5 | 61 | female | 1 | 36 | 5.8 | 2 | carboplatin + paclitaxel + pembrolizumab | 20.3 | true | MSS | 2026-03-15T05:35:58.364488+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_549907 | REC_0006148 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 30 | 16 | 52 | female | 0 | 10 | 5.6 | 1 | alectinib 600 mg BID | 25.5 | false | MSI-H | 2026-03-15T05:35:58.364726+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_662094 | REC_0006149 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 24 | 11.3 | 60 | female | 1 | 17 | 3.5 | 7 | alectinib 600 mg BID | 12.3 | false | MSS | 2026-03-15T05:35:58.364974+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_466407 | REC_0006150 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 28 | 11.5 | 50 | female | 0 | 15 | 4.1 | 5 | sotorasib 960 mg daily | 10.6 | false | MSI-H | 2026-03-15T05:35:58.365283+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_129354 | REC_0006151 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 23 | 11.6 | 73 | female | 1 | 28 | 6 | 2 | pembrolizumab 200 mg q3w | 7 | false | MSI-H | 2026-03-15T05:35:58.365523+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_603317 | REC_0006152 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 16 | 13.1 | 75 | female | 1 | 18 | 7.7 | 1 | alectinib 600 mg BID | 18.6 | true | MSI-H | 2026-03-15T05:35:58.365756+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_787662 | REC_0006153 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 25 | 12.9 | 58 | female | 0 | 21 | 7.2 | 1 | alectinib 600 mg BID | 9.8 | true | MSS | 2026-03-15T05:35:58.365992+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_320865 | REC_0006154 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 25 | 8.4 | 71 | female | 0 | 17 | 5.4 | 1 | pembrolizumab 200 mg q3w | 16.6 | true | MSS | 2026-03-15T05:35:58.366219+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_323038 | REC_0006155 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 24 | 12.6 | 61 | male | 1 | 8 | 5.1 | 2 | osimertinib 80 mg daily | 10.7 | false | MSS | 2026-03-15T05:35:58.366458+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_333500 | REC_0006156 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 25 | 12.5 | 67 | female | 0 | 2 | 5 | 5 | entrectinib 600 mg daily | 9.3 | true | MSS | 2026-03-15T05:35:58.366692+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_792251 | REC_0006157 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 21 | 20.8 | 67 | female | 1 | 13 | 6.8 | 7 | osimertinib 80 mg daily | 4 | true | MSS | 2026-03-15T05:35:58.366927+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_105678 | REC_0006158 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 20 | 7.7 | 69 | female | 1 | 9 | 4.3 | 7 | osimertinib 80 mg daily | 6.5 | false | MSS | 2026-03-15T05:35:58.367163+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_931517 | REC_0006159 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 26 | 17.3 | 57 | female | 1 | 18 | 3.8 | 6 | sotorasib 960 mg daily | 11.8 | false | MSS | 2026-03-15T05:35:58.367399+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_799981 | REC_0006160 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 27 | 12 | 57 | male | 1 | 11 | 5.3 | 7 | osimertinib 80 mg daily | 7.6 | true | MSS | 2026-03-15T05:35:58.367632+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_204900 | REC_0006161 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 21 | 13.4 | 69 | female | 0 | 17 | 4.7 | 2 | alectinib 600 mg BID | 19.3 | false | MSI-H | 2026-03-15T05:35:58.367863+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_331112 | REC_0006162 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 18 | 9.4 | 72 | female | 2 | 11 | 5.3 | 1 | osimertinib 80 mg daily | 14 | true | MSS | 2026-03-15T05:35:58.368124+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_937867 | REC_0006163 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 23 | 18.1 | 61 | male | 0 | 15 | 5.7 | 7 | sotorasib 960 mg daily | 12.1 | true | MSI-H | 2026-03-15T05:35:58.368418+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_430568 | REC_0006164 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 23 | 5.4 | 75 | female | 0 | 69 | 5.2 | 8 | carboplatin + paclitaxel + pembrolizumab | 15.1 | false | MSS | 2026-03-15T05:35:58.368654+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_987292 | REC_0006165 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 22 | 10.5 | 54 | male | 0 | 9 | 3.3 | 1 | sotorasib 960 mg daily | 18.9 | true | MSS | 2026-03-15T05:35:58.368889+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_949402 | REC_0006166 | Non-small cell lung cancer | Adenocarcinoma | IVA | None (PD-L1 high) | 24 | 11.7 | 78 | female | 1 | 24 | 4.5 | 2 | pembrolizumab 200 mg q3w | 21.5 | false | MSS | 2026-03-15T05:35:58.369123+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_263716 | REC_0006167 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 29 | 9.2 | 73 | male | 1 | 16 | 6.5 | 6 | alectinib 600 mg BID | 11.5 | false | MSS | 2026-03-15T05:35:58.369355+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_441465 | REC_0006168 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 30 | 17.4 | 75 | female | 1 | 15 | 6.2 | 5 | entrectinib 600 mg daily | 11 | true | MSI-H | 2026-03-15T05:35:58.369588+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_608804 | REC_0006169 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 26 | 14.6 | 79 | female | 0 | 7 | 3 | 1 | osimertinib 80 mg daily | 19.4 | false | MSS | 2026-03-15T05:35:58.369821+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_853617 | REC_0006170 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 28 | 3.5 | 73 | female | 1 | 39 | 5 | 1 | carboplatin + paclitaxel + pembrolizumab | 18.5 | false | MSS | 2026-03-15T05:35:58.370049+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_270816 | REC_0006171 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 24 | 6 | 66 | female | 0 | 43 | 7.7 | 0 | carboplatin + paclitaxel + pembrolizumab | 16.9 | false | MSS | 2026-03-15T05:35:58.370278+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_584149 | REC_0006172 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 26 | 11.5 | 83 | male | 1 | 18 | 5.2 | 6 | alectinib 600 mg BID | 13.3 | true | MSS | 2026-03-15T05:35:58.370515+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_136000 | REC_0006173 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 29 | 14.7 | 55 | female | 0 | 11 | 7.9 | 6 | sotorasib 960 mg daily | 14.8 | false | MSS | 2026-03-15T05:35:58.370748+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_160640 | REC_0006174 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 21 | 9.3 | 67 | female | 1 | 3 | 6 | 3 | entrectinib 600 mg daily | 15.6 | false | MSS | 2026-03-15T05:35:58.370980+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_637993 | REC_0006175 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 20 | 13 | 66 | female | 1 | 15 | 5.6 | 5 | sotorasib 960 mg daily | 10.3 | false | MSI-H | 2026-03-15T05:35:58.371211+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_497502 | REC_0006176 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 27 | 12 | 56 | female | 0 | 10 | 4.8 | 2 | osimertinib 80 mg daily | 22.1 | true | MSS | 2026-03-15T05:35:58.371497+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_885304 | REC_0006177 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 27 | 14.3 | 55 | male | 1 | 17 | 6.1 | 1 | entrectinib 600 mg daily | 12 | false | MSI-H | 2026-03-15T05:35:58.371736+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_806743 | REC_0006178 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None (PD-L1 high) | 32 | 6.6 | 66 | male | 1 | 20 | 5.1 | 1 | pembrolizumab 200 mg q3w | 15.4 | true | MSS | 2026-03-15T05:35:58.371969+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_328489 | REC_0006179 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 18 | 14.4 | 70 | male | 2 | 26 | 3.3 | 6 | sotorasib 960 mg daily | 8.8 | false | MSI-H | 2026-03-15T05:35:58.372237+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_471265 | REC_0006180 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 28 | 5 | 73 | male | 2 | 28 | 6.7 | 4 | alectinib 600 mg BID | 9 | false | MSS | 2026-03-15T05:35:58.372470+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_388653 | REC_0006181 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 28 | 10.6 | 81 | male | 1 | 15 | 6.2 | 7 | osimertinib 80 mg daily | 7.2 | false | MSS | 2026-03-15T05:35:58.372704+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_910844 | REC_0006182 | Non-small cell lung cancer | Adenocarcinoma | III | EGFR exon 19 deletion | 27 | 9.2 | 64 | female | 1 | 18 | 5 | 0 | osimertinib 80 mg daily | 19.5 | false | MSS | 2026-03-15T05:35:58.372939+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_738720 | REC_0006183 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 15 | 8.6 | 56 | male | 1 | 57 | 5.6 | 4 | carboplatin + paclitaxel + pembrolizumab | 11 | false | MSS | 2026-03-15T05:35:58.373171+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_316820 | REC_0006184 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None (PD-L1 high) | 24 | 5.7 | 76 | female | 2 | 34 | 5.1 | 1 | pembrolizumab 200 mg q3w | 12.4 | true | MSS | 2026-03-15T05:35:58.373402+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_522400 | REC_0006185 | Non-small cell lung cancer | Adenocarcinoma | III | EGFR L858R | 28 | 15.7 | 84 | male | 2 | 4 | 8 | 0 | osimertinib 80 mg daily | 64.5 | true | MSI-H | 2026-03-15T05:35:58.373637+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_339464 | REC_0006186 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 28 | 10.6 | 70 | female | 1 | 16 | 5 | 4 | alectinib 600 mg BID | 12.6 | false | MSI-H | 2026-03-15T05:35:58.373869+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_255376 | REC_0006187 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 25 | 6.9 | 68 | female | 0 | 19 | 4.3 | 2 | alectinib 600 mg BID | 22.6 | false | MSS | 2026-03-15T05:35:58.374100+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_689650 | REC_0006188 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 27 | 7.6 | 65 | male | 0 | 17 | 6.8 | 1 | pembrolizumab 200 mg q3w | 14.3 | true | MSS | 2026-03-15T05:35:58.374330+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_498964 | REC_0006189 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 25 | 8.5 | 80 | female | 0 | 15 | 5.9 | 5 | osimertinib 80 mg daily | 5.2 | true | MSS | 2026-03-15T05:35:58.374602+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_811001 | REC_0006190 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 26 | 6.5 | 56 | female | 1 | 12 | 4.5 | 1 | pembrolizumab 200 mg q3w | 13.9 | true | MSS | 2026-03-15T05:35:58.374836+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_696933 | REC_0006191 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None (PD-L1 high) | 19 | 6.3 | 55 | male | 1 | 49 | 4.7 | 2 | pembrolizumab 200 mg q3w | 13 | false | MSS | 2026-03-15T05:35:58.375072+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_305833 | REC_0006192 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 23 | 9.7 | 63 | male | 1 | 15 | 8.1 | 1 | osimertinib 80 mg daily | 19.5 | false | MSS | 2026-03-15T05:35:58.375303+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_358194 | REC_0006193 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 24 | 14.1 | 59 | male | 1 | 12 | 5.8 | 3 | osimertinib 80 mg daily | 9.1 | true | MSS | 2026-03-15T05:35:58.375539+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_416456 | REC_0006194 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 22 | 12.6 | 72 | female | 1 | 18 | 6.9 | 2 | entrectinib 600 mg daily | 16.1 | false | MSS | 2026-03-15T05:35:58.375773+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_899805 | REC_0006195 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 27 | 4 | 73 | female | 1 | 56 | 7 | 6 | carboplatin + paclitaxel + pembrolizumab | 17.3 | true | MSS | 2026-03-15T05:35:58.376003+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_959968 | REC_0006196 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 29 | 3.3 | 74 | female | 2 | 17 | 7.1 | 3 | carboplatin + paclitaxel + pembrolizumab | 6.9 | false | MSS | 2026-03-15T05:35:58.376374+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_743278 | REC_0006197 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 23 | 12.6 | 61 | female | 1 | 14 | 5.8 | 6 | sotorasib 960 mg daily | 14.7 | false | MSI-H | 2026-03-15T05:35:58.376614+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_726074 | REC_0006198 | Non-small cell lung cancer | Adenocarcinoma | III | EGFR L858R | 19 | 12.2 | 65 | male | 1 | 5 | 5.5 | 0 | osimertinib 80 mg daily | 47.3 | false | MSS | 2026-03-15T05:35:58.376852+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_748061 | REC_0006199 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 30 | 14.9 | 73 | female | 2 | 15 | 5 | 2 | osimertinib 80 mg daily | 11.4 | true | MSS | 2026-03-15T05:35:58.377085+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_653190 | REC_0006200 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 19 | 11.7 | 71 | male | 2 | 15 | 4.5 | 4 | osimertinib 80 mg daily | 15.6 | false | MSS | 2026-03-15T05:35:58.377318+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.